Arrowhead Q2 revenue $73.7M, net loss $0.93; REDEMPLO strong; $930M capital raise; Madrigal license

ARROWHEAD PHARMACEUTICALS, INC.

2026-Q2 EPS reported -$0.73 revenue$337,770,000

Q2 revenue $73.7M (down 86% YoY); net loss $132.7M ($0.93 diluted EPS) vs prior-year income $370.4M ($2.75 EPS).
REDEMPLO launch: >400 prescriptions, ~180 patients shipped, ~30 new scripts/week, 85% APOC3-naive patients.
Licensed ARO-PNPLA3 to Madrigal for $25M upfront, up to $975M milestones, tiered royalties (high-single to mid-teens).
Raised $930M: $700M zero-coupon converts due 2032 (35% premium) and $230M stock at $64.50/sh.
Obesity: ARO-INHBE combo -9.4% weight loss wk16 (vs -4.8%); ARO-ALK7 -88% mRNA knockdown, -14.1% visceral fat.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. reported financial results for fiscal 2026 second quarter ended March 31, 2026.

Period: fiscal 2026 second quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0000879407-26-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.